Free Trial
NASDAQ:CVAC

CureVac Q1 2023 Earnings Report

CureVac logo
$3.46 +0.10 (+2.95%)
Closing price 03:58 PM Eastern
Extended Trading
$3.43 -0.03 (-0.87%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CureVac EPS Results

Actual EPS
-$0.29
Consensus EPS
-$0.29
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

CureVac Revenue Results

Actual Revenue
$7.65 million
Expected Revenue
$16.45 million
Beat/Miss
Missed by -$8.80 million
YoY Revenue Growth
N/A

CureVac Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Tuesday, May 30, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

CureVac's Q1 2025 earnings is scheduled for Thursday, May 22, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

CureVac Earnings Headlines

CureVac (NASDAQ:CVAC) Shares Gap Up - Here's What Happened
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
See More CureVac Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email.

About CureVac

CureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

View CureVac Profile

More Earnings Resources from MarketBeat